Navigation Links
Cynosure Reports First-Quarter 2013 Financial Results
Date:4/30/2013

alification under the securities laws of any such jurisdiction.  No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the U.S. Securities Act of 1933, as amended.

 Consolidated Statements of Income (Unaudited)(In thousands, except per share data)Three Months Ended March 31,20132012Revenues$
40,690

$
34,168Cost of revenues 17,003

14,660Gross profit23,687

19,508Operating expensesSelling and marketing 

12,603

11,551Research and development3,781

3,239Amortization of intangible assets acquired

214

342General and administrative 

5,101

3,518Total operating expenses21,699

18,650Income from operations1,988

858Interest income, net

32

10Other (expense) income, net

(357)

209Income before income taxes1,663

1,077Income tax provision 

424

258Net income$
,239

$
819Diluted net income per share 

$
.07

$
.06Diluted weighted average shares outstanding

16,860

13,037Basic net income per share 

$
.08

$
.07Basic weighted average shares outstanding

16,185

12,578 

 Condensed Consolidated Balance Sheet (In thousands)March 31, December 31, 20132012(Unaudited)Assets:Cash, cash equivalents and marketable securities

$
89,237$
86,057Short-term investments and related financial instruments

43,77040,617Accounts receivable, net20,94517,970Inventories32,86632,906Deferred tax asset, current portion779783Prepaid expenses and other current assets5,0755,149Total current assets192,672183,482Property and equipment, net8,6888,207Long-term marketable securities13,63720,071Goodwill and intangibles, net21,37621,748Other noncurrent assets1,0161,061Total assets$
237,389$
234
'/>"/>

SOURCE Cynosure, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Cynosure Receives FDA Clearance for At-Home Device for the Treatment of Wrinkles
2. Cynosure Announces Upcoming Conference Presentations
3. Cynosure, Inc. Announces Proposed Public Offering of Class A Common Stock
4. Cynosure, Inc. Prices Public Offering of Class A Common Stock
5. Cynosure to Present at Canaccord Genuity Medical Technology & Diagnostics Forum
6. Cynosure to Host Fourth-Quarter 2012 Financial Results Conference Call on February 12
7. Cynosure to Participate in Leerink Swann Global Healthcare Conference 2013
8. Cynosure Reports Record Revenues for Fourth-Quarter and Full-Year 2012
9. Cynosure Announces Presentation of 16 Abstracts at 33rd ASLMS Annual Conference
10. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
11. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)...  Cepheid (NASDAQ: CPHD ) today announced that ... invited investors to participate via webcast. ... NY Wednesday, August 13, 2014 at 9.10 a.m. ... New York, NY Thursday, September 4, 2014 ... Webcasts To access the live webcasts for these events, please ...
(Date:7/31/2014)... , July 31, 2014 Rock Creek ... that it has initiated the development of its lead ... and that it has selected Quotient Clinical, The Translational ... (UK) to run its early development programs. ... Trial Application (CTA) by the end of the third ...
(Date:7/31/2014)... , July 31, 2014 Lazarus Effect, a ... interventional devices to facilitate removal of blood clots, announced ... the financing will support EU commercialization of several approved ... the Lazarus ReCover™ and Lazarus Cover™ in ... reflects investor confidence in the value of our novel, ...
Breaking Medicine Technology:Cepheid to Webcast Upcoming Financial Presentations 2Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 2Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 3Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 4Lazarus Effect Closes $5 Million Financing 2
... SAN DIEGO, Jan. 31 TargeGen, Inc. ... multi-center Phase I/II clinical trial of,TG101348, an ... JAK2 in,patients with myeloproliferative diseases., (Logo: ... of JAK2 is implicated in the pathogenesis ...
... Mayo clinic in key role in treatment discovery, ... New York,based company Cytopia Limited (ASX: CYT) announced ... demonstrated potent activity in cells,isolated from patients with ... of diseases where there is over-production of,particular cells ...
Cached Medicine Technology:TargeGen Announces Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients 2JAK2 Inhibitor Shows Potent Activity in Cells From MPD Patients 2
(Date:8/1/2014)... 01, 2014 The North America Sports Drink ... North America, with analysis and forecast of revenue. The Sports ... around $5,021.9 million in 2012 to $6,243 million by 2018, ... Browse through the TOC of the North America Sports Drink ... provided. This also provides a glimpse of the segmentation in ...
(Date:8/1/2014)... Society of America (GSA) the nation,s largest ... has chosen Sean P. Curran, PhD, of the University ... Nathan Shock New Investigator Award. , This distinguished honor ... aging through basic biological research. It was established in ... of GSA and pioneer in gerontological research at the ...
(Date:8/1/2014)... of electronic reminders such as text messages, emails or ... adhere to a preadmission antiseptic showering regimen known to ... to a first-of-its-kind study published in the August issue ... Surgeons . , Each year approximately 400,000 SSIs occur ... according to data sources cited by study authors. ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 Chilton ... portal that aims to empower patients and their ... their health care by providing easy, secure access ... gives patients instant, web-based access to their health ... radiology results, medications, allergies, demographic information, visit history, ...
(Date:8/1/2014)... NY (PRWEB) August 01, 2014 Ticket Down ... at Maple Lane Farms in Knoxville/Greenback, TN; Ingram Farms ... Whitehurst Cattle Farm in Archer/Gainesville, FL. Luke Bryan is currently ... with Lee Brice and Cole Swindell. Bryan is responsible for ... world each summer and this year, just because the summer ...
Breaking Medicine News(10 mins):Health News:North America Sports Drinks Market is Expected to Reach $6,243 Million in 2018 - New Report by MicroMarket Monitor 2Health News:North America Sports Drinks Market is Expected to Reach $6,243 Million in 2018 - New Report by MicroMarket Monitor 3Health News:North America Sports Drinks Market is Expected to Reach $6,243 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Curran to receive GSA's 2014 Nathan Shock New Investigator Award 2Health News:Electronic reminders can help patients prevent surgical site infections 2Health News:Electronic reminders can help patients prevent surgical site infections 3Health News:Chilton Medical Center Launches Online Patient Portal 2Health News:Luke Bryan Tickets at Maple Lane Farms in Knoxville, Ingram Farms in Auburn, Cross Creek Place in Tallahassee & Whitehurst Cattle Farm in Gainesville Now Available 2Health News:Luke Bryan Tickets at Maple Lane Farms in Knoxville, Ingram Farms in Auburn, Cross Creek Place in Tallahassee & Whitehurst Cattle Farm in Gainesville Now Available 3Health News:Luke Bryan Tickets at Maple Lane Farms in Knoxville, Ingram Farms in Auburn, Cross Creek Place in Tallahassee & Whitehurst Cattle Farm in Gainesville Now Available 4
... Eliminates Need for Cadavers and Accelerates Physician TrainingGREAT ... maker of anatomically accurate surgical training models, is ... new Maxillary Clinical Sinus Trainer. This innovative ... to train ENT surgeons on their new FinESS(TM) ...
... is a Gift that Helps Doctors Improve Health CareWINSTON-SALEM, N.C., ... 30th, DrScore.com , the physician rating Web ... feedback by rating their doctors online. "The best gift patients ... in general is honest, constructive feedback," says Steve Feldman M.D., ...
... in French . , Montreal, March ... to reality, thanks to a discovery from scientists at ... According to a study published in the journal ... first to clone, produce and purify a protein important ...
... incisionless, non-invasive procedure treats patients with chronic reflux ... Center today announced that two surgeons from its ... Washington State on Monday, March 16. EsophyX ... gastroesophageal reflux disease, or GERD. The two ...
... What can you buy with a dollar anymore? ... and treatment for those who cannot afford to battle breast ... Brandon Mendelson and the 1 in 8 Foundation are challenging ... $1 and provide care and complete support for women and ...
... on factory farmsWASHINGTON, March 17 Nearly one year ... released its landmark recommendations on how America should reform ... Slaughter today introduced the Preservation of Antibiotics for Medical ... the Federal Food, Drug, and Cosmetic Act to withdraw ...
Cached Medicine News:Health News:Chamberlain Group Surgical Training Model Facilitates New Treatment for Chronic Rhinosinusitis 2Health News:Chamberlain Group Surgical Training Model Facilitates New Treatment for Chronic Rhinosinusitis 3Health News:Rate Your Doctor at DrScore.com for Doctor's Day 2Health News:Rate Your Doctor at DrScore.com for Doctor's Day 3Health News:Researchers clone key sperm-binding proteins 2Health News:Northwest Hospital Surgeons Perform First EsophyX Procedure in Washington State 2Health News:$1 Can Make The Difference 2Health News:Pew Applauds Introduction of Preservation of Antibiotics for Medical Treatment Act 2Health News:Pew Applauds Introduction of Preservation of Antibiotics for Medical Treatment Act 3Health News:Pew Applauds Introduction of Preservation of Antibiotics for Medical Treatment Act 4
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: